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a b s t r a c t
Introduction: Levomilnacipran extended-release (ER) is an FDA-approved serotonin norepinephrine
reuptake inhibitor (SNRI) for treating major depressive disorder (MDD). SF-36v2 Health Survey outcomes
from a Phase III, randomized, double-blind, placebo-controlled study (NCT00969709) were evaluated.
Methods: Prospective and post hoc analyses of SF-36 Mental and Physical Component Summaries (MCS,
PCS), and individual domains compared pooled levomilnacipran ER doses (40, 80, 120 mg/day) with
placebo. Patients (18–65 years) had MDD, depressive episode Z8 weeks, and Montgomery–Åsberg
Depression Rating Scale total score Z30. SF-36 score changes from baseline to Week 8 were analyzed
using ANCOVA and the observed cases approach (Intent-to-Treat [ITT] Population). Minimally important
differences (MID) evaluated clinical relevance.
Results: Baseline MCS scores reﬂected marked mental deﬁcits in the ITT Population (levomilnacipran
ER¼529; placebo¼175). MCS change at Week 8 was signiﬁcantly greater for levomilnacipran ER than
placebo (LSMD [SE]¼4.8 [1.5]; P¼0.0011); MID exceeded the 3-point threshold. Baseline PCS scores
suggested minimal physical deﬁcits; no between-group difference at Week 8 was noted. LSMD was
nominally statistically signiﬁcant (Po0.05) for levomilnacipran ER versus placebo in 5 domains (General
Health [2.44; P¼0.0010], Vitality [2.48; P¼0.0307], Social Functioning [3.25; P¼0.0097], Role-Emotional
[3.38; P¼0.0078], Mental Health [4.34; P¼0.0005]); changes in Vitality, Social Functioning, and Mental
Health exceeded MID.
Limitations: The trial was limited by short duration; analyses were post hoc and adjustments were not
made for multiplicity.
Conclusion: Statistically signiﬁcant and clinically meaningful improvement on the MCS and several
individual domains suggest overall and dimensional improvement in health-related functioning for
patients with MDD treated with levomilnacipran ER versus placebo.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Major depressive disorder (MDD) is one of the leading causes of
worldwide disease burden (Mathers and Loncar, 2006). The
correlation between MDD and signiﬁcant impairment in daily
functioning is widely recognized. Approximately 60% of patients
with MDD report considerable impairment (Kessler et al., 2003)
and even after treatment, many patients report symptoms that
continue to affect health-related quality of life (Fava et al., 2007;
Fava et al., 2006). Global social functioning is sometimes used as
an endpoint in clinical trials of antidepressants (Bech, 2005), but
this represents just one dimension of health-related quality of life
(Hirschfeld et al., 2000). As such, other domains of patient health
and well-being are attracting attention as ways to provide more
comprehensive evaluation of patient improvement (McKnight and
Kashdan, 2009). By assessing the mental and physical components
of depression in addition to symptom reduction, the focus of
antidepressant treatment may expand to include the concepts of
overall patient health and well-being (Bech, 2005).
The SF-36 Health Survey (SF-36) (Ware, 2000; Ware and
Sherbourne, 1992) was designed to determine the health outcomes
of general psychiatric and medical conditions in a medical setting. It
is a 36-question patient-rated health survey used to evaluate
functional health and well-being. There are 8 individual scales that
evaluate domain-speciﬁc functioning. Raw scores are transformed
into scores relative to general population norms; normative scores
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are available for a variety of countries and population subgroups. A
Physical Component Summary (PCS) and Mental Component Sum-
mary (MCS) score are generated from the individual scales. In
addition to the individual health domains and the component
summary scores, the SF-36 can also be used to derive a single
index health state classiﬁcation measure known as the SF-6D
(Brazier et al., 1998). The SF-36 may be used in a wide range of
applications across various populations and disease states, including
depression; only a limited number of antidepressant clinical trials
have used the SF-36 scale to supplement symptom-based depres-
sion rating scales in MDD (Bech, 2005).
Nonclinical studies have shown that levomilnacipran (1S, 2R-
milnacipran) is a potent and selective serotonin (5-HT) and
norepinephrine (NE) reuptake inhibitor (SNRI). Levomilnacipran
has greater potency for inhibition of norepinephrine reuptake
relative to serotonin reuptake (Auclair et al., 2013). An extended-
release (ER) formulation of levomilnacipran that allows for once-
daily dosing has been approved by the United States Food and
Drug Administration (FDA) for the treatment of MDD in adults. The
efﬁcacy of levomilnacipran ER was established in 3 positive
8-week, randomized, placebo-controlled trials (Asnis et al., 2013;
Bakish et al., 2014; Sambunaris et al., 2013). Levomilnacipran ER
was generally well tolerated in all studies.
The effect of levomilnacipran ER on function, health, and well-
being in adult patients with MDD was evaluated in participants
from one of the Phase III studies (Asnis et al., 2013) in which the
SF-36v2 survey (Ware, 2000; Ware et al., 2007) was a prospec-
tively included outcome measure. In this study, statistically sig-
niﬁcant improvement was observed on the primary outcome
measure, mean MADRS total score change from baseline to
Week 8, in all levomilnacipran ER dose groups (least squares
mean differences [LSMD] versus placebo: 40 mg/day¼3.2;
80 mg/day¼4.0; 120 mg/day¼4.9). Levomilnacipran ER also
demonstrated superiority over placebo on functional outcomes
measured by total score change from baseline on the Sheehan
Disability Scale (SDS) (Sheehan et al., 1996). Protocol-deﬁned and
post hoc analyses of SF-36 outcomes were undertaken to enhance
the current body of clinical trial literature pertaining to health-
related outcomes in depression.
2. Materials and methods
2.1. Study design
This 11-week study (NCT00969709) was a positive Phase III,
ﬁxed-dose, placebo-controlled, double-blind, randomized clinical
trial of levomilnacipran ER 40 mg, 80 mg, or 120 mg conducted in
patients with MDD (Asnis et al., 2013); the study comprised a
1-week, single-blind placebo run-in period, 8 weeks of double-
blind treatment, and a 2-week, double-blind down-taper period.
Levomilnacipran ER was initiated at 20 mg/day with a dose
increase to 40 mg/day on Day 2; the 80-mg/day and 120-mg/day
target doses were reached on Day 5 and Day 8, respectively. The
SF-36 was administered at baseline (Week 0) and at the end of
treatment (Week 8); a detailed description of the primary study
design, inclusion and exclusion criteria, methods, and primary
results has been previously published (Asnis et al., 2013).
2.2. Key inclusion criteria
Male or female patients (18–65 years of age, inclusive) who met
criteria for MDD as deﬁned by the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, text revision, (DSM-IV-TR) (APA, 2000),
had a current ongoing depressive episode Z8 weeks' duration,
and total score Z30 on the clinician-rated Montgomery–Åsberg
Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979)
were included. Patients had to have normal physical and laboratory
ﬁndings or abnormal ﬁndings that were not judged to be clinically
signiﬁcant.
2.3. Key exclusion criteria
Principal reasons for exclusion included a primary DSM-IV-TR
Axis I diagnoses other than MDD; history of various psychiatric
diagnoses (e.g., manic/hypomanic episode [lifetime], substance
abuse/dependence [prior 6 months]); concurrent medical condi-
tions that might have interfered with the conduct of the study,
confounded the interpretation of study results, or endangered
patient well-being; nonresponse to Z2 antidepressants; signiﬁ-
cant suicide risk; or concomitant use of psychoactive medications
(except eszopiclone, zolpidem or zaleplon for sleep).
2.4. Prospective and post hoc outcome measures
The outcome of interest in these analyses was the SF-36 Health
Survey version 2 (Acute 1-week recall) (Ware et al., 2007). The
component summary scores (MCS and PCS) were analyzed pro-
spectively in the primary trial; the individual domain scores,
which were calculated as part of determining the MCS and PCS,
were evaluated in post hoc analyses. MCS and PCS summary scores
were calculated by aggregating individual domain scores, which
are multiplied by a factor score coefﬁcient. Each of the individual
domain scales relatively contribute to the scoring of both MCS and
PCS component summary scores (Ware, 2000). Data from the 1998
National Survey of Functional Health Status were used to develop
norm-based scores (NBS) for the component summary scales and
individual domain scores based on algorithms that transform the
0–100 scores to a T-score metric with a mean of 50 and a standard
deviation (SD) of 10 in the US general population (Ware, 2000).
Higher scores are indicative of better health and score increases
represent improvement.
On the individual health domains, scores within 3 NBS points
or 0.3 SD of the population norm are considered “average” or
“normal,” indicating that scores less than 47 are below average
(Ware, 2000; Ware et al., 2007). Between-group differences of 2–4
points are considered to be clinically meaningful depending on the
domain or component being measured; minimally important
difference (MID) thresholds have been determined for each
individual domain and the summary scales to assess the clinical
relevance of treatment (Ware et al., 2007) (Table 1); differences
that equal or exceed the MID suggest that the improvements were
clinically relevant.
The SF-6D, which is derived from 11 items in the SF-36,
provides an index score that ranges from 0.0 (worst health state)
to 1.0 (best health state) using the standard gamble valuation
technique to obtain utility values for various health states; MID
values for the SF-36 have been previously determined (Gandhi
et al., 2012).
2.5. Statistical analyses
Change from baseline to Week 8 on SF-36 component summa-
ries (MCS and PCS) and individual health domain scores were
computed based on the Intent-to-Treat (ITT) Population, which
consisted of all patients who received study medication and Z1
postbaseline MADRS total score assessment. Analyses were con-
ducted on the completer population using the the observed cases
(OC) approach; a sensitivity analysis used the last observation
carried forward (LOCF) approach to impute missing data. OC
results include only those patients who completed 8 weeks of
double-blind treatment, while the LOCF analysis also includes
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patients that may have terminated from the study early. Outcomes
only included subjects who had evaluable data; for example, while
it may not have been possible to calculate some individual domain
scores due to missing data, it may have still been possible to
calculate component summary scores. Levomilnacipran ER indivi-
dual dose groups (40 mg/day, 80 mg/day, or 120 mg/day) were
pooled to calculate the least squares (LS) mean change from
baseline and LS mean difference (LSMD) versus placebo on the
SF-36 component summaries and individual health domains. An
analysis of covariance (ANCOVA) model, adjusting for treatment
group, pooled study site, and baseline value of the underlying
score was used. When study centers were small (o4 patients),
they were pooled to form a larger pseudo-center study site.
Additionally, an ANCOVA model similar to what was used in the
pooled analyses was used to compare the individual levomilnacipran
ER dose groups versus placebo on change from baseline in MCS, PCS,
and individual domain scores. P values were based on Dunnett–Hsu
adjustment for multiple comparisons between individual dose levels
and placebo. Signiﬁcance was determined at the 0.05 level.
3. Results
3.1. Patient disposition and baseline demographics
In the primary MADRS analysis, 704 patients (placebo¼175;
levomilnacipran ER¼529) received study drug and had at least
1 postbaseline MADRS assessment (ITT Population). Baseline
demographics and clinical characteristics were similar between
treatment groups; the mean (SD) age of patients was 41 (12) years
and 63% were women. The mean baseline MADRS score was 36 for
placebo and levomilnacipran ER groups.
Mean (SD) baseline scores on the MCS were 17.3 (9.3) for placebo
and 18.2 (8.6) for levomilnacipran ER. Since these values were greater
than 0.3 SD from the norm, it indicated signiﬁcant mental health
deﬁcits in both treatment groups. Mean (SD) baseline scores on the
PCS were 52.3 (11.1) for placebo and 50.6 (11.1) for levomilnacipran
ER, which is slightly higher than the population norm (50), indicating
a study population with normal physical functioning. However, since
the PCS is calculated by incorporating the factor score coefﬁcients for
each domain, decrements in some individual health domains,
particularly Role-Physical, were apparent at baseline (Table 2).
The baseline scores for all individual domains except Physical
Functioning, which was considered within the average or normal
range, were below average (Table 2). Baseline deﬁcits in excess of
1 SD from the norm were noted for both levomilnacipran ER and
placebo in Vitality, Social Functioning, Role-Emotional, and Mental
Health. Baseline SF-6D scores were 0.5526 (0.07) for placebo and
0.5435 (0.06) for levomilnacipran ER.
3.2. Group mean changes
3.2.1. Mental and physical component summary scores
After 8 weeks of randomized double-blind treatment, LS mean
(SE) change from baseline in MCS score was signiﬁcantly greater
Table 1
Criteria used for minimally important differences.
Scale MID criteria used for mean
group-level comparisonsa
Physical Functioning (PF)b 3 NBS points
Role-Physical (RP)b 2 NBS points
Bodily Pain (BP)b 3 NBS points
General Health (GH)b 3 NBS points
Vitality (VT)b 3 NBS points
Social Functioning (SF)b 3 NBS points
Role-Emotional (RE)2 3 or 4 NBS pointsd
Mental Health (MH)b 3 NBS points
Physical Component Summary (PCS)b 2-3 NBS points
Mental Component Summary (MCS)b 3 NBS points
SF-6D Health Utility Indexc 0.03 Index points
MID indicates minimally important differences.
a These are anchor-based minimally important differences based on baseline
values as indicated by Ware et al. (2007).
b Ware, J.E., Jr., Kosinski, M., Bjorner, J.B., Turner–Bowker, D.M., Gandek, B.,
Maruish, M.E., 2007. User's Manual for the SF-36v2s Health Survey (2nd ed.).
Lincoln, RI: QualityMetric Incorporated.
c Gandhi, P.K., Ried, L.D., Bibbey, A., Huang, I.C., 2012. SF-6D utility index as a
measure of minimally important difference in health status change. Journal of the
American Pharmacists Association: JAPhA 52, 34–42.
d For Role-Emotional, a 4-point difference is considered to be clinically mean-
ingful for most diseases states evaluated; however, a 3-point difference in Role-
Emotional has been shown to be clinically meaningful in depression.
Table 2
SF-36 Individual health domains: Mean (SD) baseline and end of treatment scores (ITT Population, OC).
Individual health domains Placebo n¼175a Mean (SD) Levomilnacipran ER n¼529a Mean (SD) LSMD (SE) P Value
Physical health domains
Physical Functioning Baseline score 46.7 (10.4) 45.3 (10.8) — —
Score at Week 8 49.1 (10.4) 48.4 (10.0) 0.58 (0.8) 0.4713
Role-Physical Baseline score 41.5 (13.1) 40.3 (12.5) — —
Score at Week 8 45.5 (11.5) 45.4 (11.3) 0.56 (1.0) 0.5648
Bodily Pain Baseline score 44.0 (11.1) 43.0 (10.7) — —
Score at Week 8 47.4 (10.9) 46.9 (10.6) 0.52 (0.9) 0.5438
General Health Baseline score 42.8 (9.1) 41.7 (9.7) — —
Score at Week 8 45.7 (10.3) 47.0 (10.0) 2.44 (0.7) 0.0010
Mental health domains
Vitality Baseline score 30.4 (6.5) 30.5 (6.8) — —
Score at Week 8 38.6 (12.2) 40.8 (12.1) 2.48 (1.1)b 0.0307
Social Functioning Baseline score 25.1 (8.6) 25.5 (8.6) — —
Score at Week 8 35.3 (13.6) 38.5 (13.2) 3.25 (1.3)b 0.0097
Role-Emotional Baseline score 23.9 (9.9) 24.4 (10.0) — —
Score at Week 8 34.3 (13.4) 37.6 (13.7) 3.38 (1.3)c 0.0078
Mental Health Baseline score 24.1 (8.0) 23.9 (7.7) — —
Score at Week 8 34.3 (13.4) 38.5 (13.0) 4.34 (1.2)b 0.0005
a Analyses were based on the observed cases (OC) population (n¼142, placebo; n¼372, levomilnacipran ER).
b Exceeds the threshold for minimally important differences (MID) for group level data.
c Below the MID of 4, although a 3-point difference in Role-Emotional has been shown to be meaningful in depression. ER indicates extended-release; LS, least squares
mean difference; SE, standard error.
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for levomilnacipran ER patients (16.8 [0.8]) compared with pla-
cebo patients (12.0 [1.3]) (LSMD [SE]¼4.8 [1.5]; P¼0.0011) (Fig. 1).
No statistically signiﬁcant difference in PCS score change from
baseline was noted between treatment groups (LSMD [SE]¼0.4
[0.8]; P¼0.5859) (Fig. 1). Unlike baseline MCS scores, which indicated
considerable mental health decrements in both treatment groups,
baseline PCS scores were normal, making the potential for relevant
improvement small.
3.2.2. Individual health domain scores
The difference in mean score change from baseline to Week 8 was
statistically signiﬁcant in favor of levomilnacipran ER versus placebo
on all mental health individual domains and 1 physical health
individual domain: General Health, Vitality, Social Functioning,
Role-Emotional, and Mental Health (Table 2, Fig. 2). Differences were
not statistically signiﬁcant for levomilnacipran ER versus placebo in
Physical Functioning, Role-Physical, and Bodily Pain (Table 2, Fig. 2). It
is of note that baseline values for these domains were within 1 SD of
the population norm; a trend toward improvement was noted in
Physical Functioning, Role-Physical, and Bodily Pain scores for
patients treated with levomilnacipran ER.
The statistically signiﬁcant differences in LS mean change from
baseline to Week 8 in favor of levomilnacipran ER versus placebo
also exceeded the MID in the domains of Vitality, Social Function-
ing, and Mental Health, suggesting that improvement in the
levomilnacipran ER group may have been clinically relevant in
these areas (Fig. 2). While the between-group difference in change
Fig. 1. Change from baseline to Week 8 in the mental and physical component summary scores of the SF-36 (ITT Population, OC). ER indicates extended-release; LSMD, least
squares mean difference; MID, minimally important difference; SE, standard error. **Po0.05 and exceeds MID.
Fig. 2. LS mean change from baseline in SF-36 individual health domain scores (ITT Population, OC). ER indicates extended-release; LS, least squares; PF, Physical
Functioning; RP, Role-Physical; BP, Bodily Pain; GH, General health; VT, Vitality; SF, Social Functioning; RE, Role-Emotional; MH, Mental Health. *P o .05 vs placebo;
** P o .05 vs placebo and difference exceeds the threshold for minimally important differences.
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from baseline was statistically signiﬁcant for levomilnacipran ER
for the General Health domain, it did not exceed the MID thresh-
old. Similarly, statistical difference in favor of levomilnacipran ER
over placebo was observed for Role-Emotional, but the MID
threshold of 4 was not met; in this domain, however, the ﬁnding
is equivocal since a 3-point difference has been accepted in clinical
trials to be meaningful for depression (Ware et al., 2007).
3.2.3. SF-6D
After 8 weeks of randomized double-blind treatment, LS mean
(SE) change from baseline in the SF-6D index score was signiﬁcantly
greater for levomilnacipran ER patients (0.103 [0.0068]) than placebo
patients (0.070 [0.011]; LSMD [SE]¼0.033 [0.012]; P¼0.0061) and
exceeded the 0.03 threshold for clinical signiﬁcance.
3.2.4. Sensitivity analysis
A sensitivity analysis using the LOCF approach to include patients
who discontinued the study early and did not complete a full 8
weeks of double-blind treatment supported the primary results for
levomilnacipran ER versus placebo on the MCS (LSMD [SE]¼4.4 [1.4];
P¼0.0013) and the PCS (LSMD [SE]¼0.2 [0.7]; P¼0.8386). For the
individual health domains, signiﬁcant differences in favor of levo-
milnacipran ER, which were also considered clinically relevant, were
noted in Vitality (2.4 [1.1], P¼0.0228), Social Functioning (3.1 [1.2];
P¼0.0086), Role-Emotional (3.1 [1.2]; P¼0.0097) and Mental Health
(4.3 [1.2]; P¼0.0003); for General Health, differences between
levomilnacipran ER and placebo were statistically signiﬁcant but
did not meet the MID threshold (2.3 [0.7]; P¼0.0007). Nonsigniﬁcant
differences were noted for Physical Functioning (1.0 [0.8]), Role-
Physical (0.9 [0.9]), and Bodily Pain (0.2 [0.8]).
3.3. Analyses of individual levomilnacipran ER dose groups
When differences between levomilnacipran ER and placebo
were examined by dose level, a dose-related trend was noted.
Levomilnacipran ER 80 mg/day and 120 mg/day versus placebo
produced statistically signiﬁcant change and exceeded the MID
threshold on the MCS; the 40 mg/day dose did not separate from
placebo on the MCS or any other health domain score. Higher
doses of levomilnacipran ER compared with placebo also produced
statistically signiﬁcant change and exceeded the MID threshold on
several individual domains (Fig. 3).
4. Discussion
MDD has a substantial impact on a patient's functional health
and well-being (McKnight and Kashdan, 2009). SF-36 data from a
Phase III trial in patients with MDD who were treated with 40-mg,
80-mg, or 120-mg levomilnacipran ER were pooled for analyses.
Results showed that levomilnacipran ER was associated with
statistically signiﬁcant improvement in functional health and
well-being relative to placebo as measured by the MCS of the
SF-36. Statistically signiﬁcant improvements were also observed
for levomilnacipran ER- compared with placebo- treated patients
on the individual domains of General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health. When the levo-
milnacipran ER doses were evaluated separately, statistical sig-
niﬁcance versus placebo and clinical relevance were observed on
more individual domains as the dose level increased, suggesting a
potential dose response.
Minimal difference thresholds have been previously determined
to indicate the clinical relevance of change in MCS, PCS, and
individual health domain scores (Ware et al., 2007). Improvements
that were clinically meaningful, as well as statistically signiﬁcant,
compared with placebo were observed for pooled doses of levo-
milnacipran ER on the MCS, and the individual domains of Vitality,
Social Functioning and Mental Health; although it did not exceed
the MID of 4 NBS points, the difference on Role-Emotional was still
large enough to be considered clinically meaningful for patients
with depression (Ware et al., 2007).
The association between depressive disorders and diminished
physical function has been well established (Goodwin, 2006; Trivedi,
2004). Baseline PCS scores for levomilnacipran ER and placebo in the
present analysis were slightly above the US population-based norm,
indicating that patients in this study did not have the marked
physical deﬁcits that are often associated with MDD. Additionally,
Fig. 3. Least squares mean difference for individual levomilnacipran ER doses versus placebo (ITT Population, OC) on the SF-36 component summaries and individual
domains. P values were based on Dunnett–Hsu adjustment for multiple comparisons. ER indicates extended-release; LSMD; least squares mean difference; MCS, Mental
Component Summary; PCS, Physical Component Summary; PF, Physical Functioning; RP, Role-Physical; BP, Bodily Pain; GH, General health; VT, Vitality; SF, Social
Functioning; RE, Role-Emotional; MH, Mental Health. nPo .05 vs placebo; nn Po .05 vs placebo and difference exceeds MID.
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on individual domains that predominantly measure pain or physical
functioning (e.g., Physical Functioning, Role-Physical, Bodily Pain),
baseline scores were within 1 SD of the population norm. The scores
for Role-Physical and Bodily Painwere considered below average (not
within 0.3 SD of the population norm), while Physical Functioning
was within the average range. Since physical functioning at baseline
was normal compared with the general population, the noted lack of
treatment effect for levomilnacipran ER versus placebo on the PCS
was not unexpected.
Conversely, baseline scores on the MCS and individual domains
that predominantly measure mental, affective, and social dimen-
sions (eg, Social Functioning, Role-Emotional, and Mental Health)
reﬂected a population with signiﬁcant deﬁcits at the beginning of
the study. A correlation has been observed between higher levels
of depression symptom severity and worse functional health and
well-being (Guico-Pabia et al., 2012; Trivedi, 2004); this associa-
tion is supported by high baseline MADRS total scores (36 in
both groups) and low baseline MCS scores in this study popula-
tion. The magnitude of change in MCS was both statistically
signiﬁcant and clinically meaningful in favor of levomilnacipran
ER compared with placebo, suggesting that patients with con-
siderable deﬁcits in mental health functioning and highly sympto-
matic MDD at baseline signiﬁcantly beneﬁtted from treatment
with levomilnacipran ER over the course of 8 weeks.
The SF-36 is designed to assess health outcomes across a wide
range of populations and diseases, including MDD. Nonrando-
mized depression trials have demonstrated that the SF-36 sub-
scales are relevant patient-rated outcomes (Coulehan et al., 1997;
Gleason et al., 2002; Russell et al., 2001; Simon et al., 1996;
Souetre et al., 1996); however, information regarding SF-36 assess-
ment in antidepressant clinical trials is sparse. In one 6-week,
randomized, placebo-controlled trial of ﬂuoxetine, outcomes on
SF-36 individual domains assessed health outcomes in patients
with MDD who were 60 years or older (Heiligenstein et al., 1995).
Compared with national norms for individuals over age 60,
patients had baseline decrements in Mental Health, Role-Emo-
tional, Social Functioning, Vitality, Physical Functioning, and Bodily
Pain domains. Statistically signiﬁcant differences, which were also
considered clinically meaningful, in favor of ﬂuoxetine versus
placebo were observed on the individual domains of Mental
Health, Role-Emotional, Physical Functioning, and Bodily Pain
(Po0.05). In an open-label trial, patients were randomly assigned
to paroxetine, ﬂuoxetine, or sertraline and change in MCS at 1, 3, 6,
and 9 months was evaluated as the primary outcome parameter
(Kroenke et al., 2001). Mean increases from baseline in MCS score
at 3 and 9 months, respectively, were 13.3 and 15.8 for paroxetine,
13.4 and 15.1 for ﬂuoxetine, and 15.2 and 17.4 for sertraline,
suggesting improvement occurred over time for each drug.
In the present levomilnacipran ER analyses, interpretation of
results is limited by the 8-week duration of the trial, which may
not be long enough to show maximal treatment effects. In
addition, unlike the analyses for multiple comparisons between
individual doses and placebo that were adjusted for multiplicity
using the Dunnet–Hsu method, analyses assessing multiple
domains were not controlled or adjusted for multiple compari-
sons. Since these analyses were not speciﬁcally designed to
measure dose response, ﬁndings pertaining to treatment effect
for individual dose levels cannot be considered conclusive. The
selection of patients in the primary trial was guided by inclusion
and exclusion criteria that may limit the generalizability of results.
In addition, since no active comparator was used, no conclusions
relative to other agents can be drawn.
Treatment outcomes in depression require consideration of
health-related functional decline, impairment, and improvement
in addition to the resolution of depressive symptoms. For patients
with depression, deﬁcits in social and physical functioning that
persist after depressive symptoms have resolved are associated
with decreased likelihood of recovery and increased likelihood of
recurrence (Faravelli et al., 1986; Judd and Akiskal, 2000; Judd
et al., 2000; Solomon et al., 2004; Spijker et al., 2004). Since
depression symptom measures lack domain-speciﬁc functional
information (McKnight and Kashdan, 2009), the addition of the
SF-36 outcomes such as these allows the effectiveness of anti-
depressant treatment in patients with MDD to be evaluated by
multidimensional concepts. Using the SF-36 to assess patient
functioning and well-being may be an informative way to evaluate
health outcomes in antidepressant clinical trials.
5. Conclusions
In these analyses, patients with MDD had substantial deﬁcits in
mental health-related functioning at baseline. Patients treated
with levomilnacipran ER compared with placebo achieved statis-
tically signiﬁcant and clinically meaningful improvement on the
MCS; this was true when 40 mg/day, 80 mg/day, and 120 mg/day
doses of levomilnacipran ER were pooled, and for the 80 mg/day
and 120 mg/day doses analyzed individually. Statistically signiﬁ-
cant and clinically meaningful differences in favor of levomilnaci-
pran ER were also seen on several individual domains of the SF-36,
suggesting dimensional as well as overall improvement in health-
related functioning and well-being for patients with MDD.
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